Autoimmune thyroid disease: New models of cell death in autoimmunity

Nature Reviews Immunology

Volumn 2, Issue 3, 2002, Pages 195-204

  Stassi, Giorgio ^a   De Maria, Ruggero ^b  

^a UNIVERSITY OF PALERMO   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CELL DEATH RECEPTOR; CELL RECEPTOR; CRYPTIC EPITOPE; CYTOKINE; EPITOPE; THYROID ANTIBODY; UNCLASSIFIED DRUG; FAS ANTIGEN; FAS LIGAND; FASLG PROTEIN, HUMAN; MEMBRANE PROTEIN;

ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; APOPTOSIS; AUTOIMMUNE DISEASE; AUTOIMMUNE THYROID DISEASE; AUTOIMMUNITY; CELL DEATH; CELL LOSS; CELL SURVIVAL; CENTRAL TOLERANCE; CYTOTOXIC T LYMPHOCYTE; ENDOCRINE OPHTHALMOPATHY; GERMINAL CENTER; GOITER; GRAVES DISEASE; HASHIMOTO DISEASE; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; T LYMPHOCYTE; TARGET CELL DESTRUCTION; THYROID CELL; THYROID DISEASE; AUTOIMMUNE THYROIDITIS; IMMUNOLOGY; PATHOLOGY; THYROID GLAND;

ANTIGENS, CD95; APOPTOSIS; AUTOIMMUNITY; FAS LIGAND PROTEIN; GRAVES DISEASE; HUMANS; MEMBRANE GLYCOPROTEINS; MODELS, ANIMAL; T-LYMPHOCYTES, CYTOTOXIC; THYROID GLAND; THYROIDITIS, AUTOIMMUNE;

EID: 0036514975     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri750     Document Type: Review

References (95)

1. Sinha, A. A. Lopez, M. T. & McDevitt, H. O. Autoimmune diseases: the failure of self tolerance. Science 248, 1380-1388 (1990).
2. Metcalfe, K. A. et al. Concordance for type 1 diabetes in identical twins is affected by insulin genotype. Diabetes Care 24, 838-842 (2001).
3. Brix, T. H., Kyvik, K. O. & Hegedus, L. A population-based study of chronic autoimmune hypothyroidism in Danish twins. J. Clin. Endocrinol. Metab. 85, 536-539 (2000).
4. Wesselborg, S., Janssen, O. & Kabelitz, D. Induction of activation-driven death (apoptosis) in activated but not resting peripheral blood T cells. J. Immunol. 150, 4338-4345 (1993).
5. Klas, C., Debatin, K. M., Jonker, R. P., & Krammer, P. H. Activation interferes with the APO-1 pathway in mature human T cells. Int. Immunol. 5, 625-630 (1993). The first demonstration that activated T cells become susceptible to CD95-induced apoptosis.
6. Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M. & Toda. M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155, 1151-1164 (1995). Identification of a key population of regulatory T cells.
7. + T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J. Immunol. 160, 1212-1218 (1998).
8. Wucherpfennig, K. W. & Strominger, J. L. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 80, 695-705 (1995).
9. Olson, J. K., Croxford, J. L., Calenoff, M. A., Dal Canto, M. C. & Miller S. D. A virus-induced molecular mimicry model of multiple sclerosis. J. Clin. Invest. 108, 311-318 (2001).
10. Lehmann, R. P. V., Forsthuber, T., Miller, A. & Sercarz, E. E. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 358, 155-157 (1992).
11. Bachmaier, K. et al. Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b. Nature 403, 211-216 (2000).
12. Robey, E. & Urbain. J. Tolerance and immune regulation Immunol. Today 12, 175-177 (1991).
13. Wucherpfennig. K. W. & Eisenbarth, G. S. Type 1 diabetes. Nature Immunol. 2, 767-768 (2001).
14. Steinman, L. Multiple sclerosis: a two-stage disease. Nature Immunol. 2, 762-764 (2001).
15. Weetman, A. P. & McGregor, A. M. Autoimmune thyroid disease: further developments in our understanding Endocr. Rev. 15, 788-830 (1994). A comprehensive review on thyroid autoimmunity.
16. Giordano, C. et al. Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. Science 275, 960-963 (1997).
17. De Maria, R. & Testi, R. Fas-FasL interactions: a common pathogenetic mechanism in organ-specific autoimmunity. Immunol. Today 19, 121-125 (1998).
18. Stassi, G. et al. Fas/Fas ligand-driven T cell apoptosis as a consequence of ineffective thyroid immunoprivilege in Hashimoto's thyroiditis. J. Immunol. 162, 263-267 (1999). Unexpected findings indicating that thyrocytes kill infiltrating T cells in Hashimoto's thyroiditis.
19. Stassi, G. et al. Control of target cells survival in thyroid autoimmunity by T helper cytokines via regulation of apoptotic proteins Nature Immunol. 1, 1-6 (2000). A demonstration that production of T-helper cytokines promotes survival or death of thyrocytes during the autoimmune response.
20. Davies, T. F., Roti, E., Braverman, L. E. & DeGroot, L. J. Thyroid controversy - stimulating antibodies. J. Clin. Endocrinol. Metab. 83, 3777-3785 (1998).
21. Todd, I., Pujol-Borrell, R., Hammond, L. J., Bottazzo, G. F. & Feldmann, M. Interferon-γ induces HLA-DR expression by thyroid epithelium. Clin. Exp. Immunol. 61, 265-273 (1985).
22. Hamilton, F., Black, M., Farquharson, M. A., Stewart, C. & Foulis, A. K. Spatial correlation between thyroid epithelial cells expressing class II MHC molecules and interferon-γ-containing lymphocytes in human thyroid autoimmune disease. Clin. Exp. Immunol. 83, 64-68 (1991).
23. Shimojo, N. et al. Induction of Graves-like disease in mice by immunization with fibroblasts transfected with the thyrotropin receptor and a class II molecule. Proc. Natl Acad. Sci. USA 93, 11074-11079 (1996). The first experimental model of Graves' disease.
24. Kita, M. et al. Regulation and transfer of a murine model of thyrotropin receptor antibody mediated Graves' disease. Endocrinology 140, 1392-1398 (1999).
25. Costagliola, S. et al. Genetic immunization of outbred mice with thyrotropin receptor cDNA provides a model of Graves' disease. J. Clin. Invest. 105, 803-811 (2000). Description of a new model of Graves' disease that shows lymphocytic infiltration and ophthalmopathy.
26. Dietrich, H. M., Oliveira-dos-Santos, A. J. & Wick, G. Development of spontaneous autoimmune thyroiditis in Obese strain (OS) chickens. Vet. Immunol. Immunopathol. 57, 141-146 (1997),
27. Wright, J. R., Jr, Senhauser, D. A., Yates, A. J., Sharma, H. M. & Thibert, P. Spontaneous thyroiditis in BB Wistar diabetic rats. Vet. Pathol. 20, 522-530 (1983). Description of a spontaneous model of autoimmune thyroiditis in mammals.
28. Rasooly, L., Burek, C. L. & Rose, N. R. Iodine-induced autoimmune thyroiditis in NOD-H-2h4 mice. Clin. Immunol. Immunopathol. 81, 287-292 (1996).
29. Tomazic, V. & Rose, N. R. Autoimmune murine thyroiditis. VIII. Role of different thyroid antigens in the induction of experimental autoimmune thyroiditis. Immunology 30, 63-68 (1976). One of the concluding papers of the initial description of the experimental autoimmune thyroiditis model.
30. Romball, C. G. & Weigle, W. O. Transfer of experimental autoimmune thyroiditis with T cell clones. J. Immunol. 138, 1092-1098 (1987). Demonstration that thyroid-specific T-cell clones can transfer autoimmune thyroiditis.
31. Knight, S. C. et al. Induction of autoimmunity with dendritic cells: studies on thyroiditis in mice. Clin. Immunol. Immunopathol. 48, 277-289 (1988).
32. - cells by rat monoclonal antibodies alters the development of adoptively transferred experimental autoimmune thyroiditis. Cell. Immunol. 122, 377-390 (1989).
33. Parish, N. M., Roitt, I. M. & Cooke, A. Phenotypic characteristics of cells involved in induced suppression to murine experimental autoimmune thyroiditis. Eur. J. Immunol. 18, 1463-1477 (1988).
34. Vladutiu, A. O. Experimental autoimmune thyroiditis in mice chronically treated from birth with anti-IgM antibodies Cell. Immunol. 121, 49-59 (1989).
35. Braley-Mullen, H. et al. Interleukin-12 promotes activation of effector cells that induce a severe destructive granulomatous form of murine experimental autoimmune thyroiditis, Am. J. Pathol. 152, 1347-1358 (1998). Description of a destructive model of experimental autoimmune thyroiditis.
36. Kalderon, A. E. & Bogaars, H. A. Immune complex deposits in Graves' disease and Hashimoto's thyroiditis Am. J. Med. 63, 729-734 (1977). First demonstration of immune-complex deposits in thyroid autoimmunity.
37. Weetman, A. P., Cohen, S. B., Oleesky, D. A. & Morgan, B. P. Terminal complement complexes and C1/C1 inhibitor complexes in autoimmune thyroid disease. Clin. Exp. Immunol. 77, 25-30 (1989).
38. Khoury, E. L., Hammond, L., Bottazzo, G. F. & Doniach, D. Presence of the organ-specific 'microsomal' autoantigen on the surface of human thyroid cells in culture: its involvement in complement-mediated cytotoxicity. Clin. Exp. Immunol. 45, 316-328 (1981).
39. Bogner, U., Schleusener, H. & Wail, J. R. Antibody-dependent cell mediated cytotoxicity against human thyroid cells in Hashimoto's thyroiditis but not Graves' disease. J. Clin. Endocrinol. Metab. 59, 734-738 (1984).
40. Guo, J., Jaurne, J. C., Rapoport, B. & McLachlan, S. M. Recombinant thyroid peroxidase-specific Fab converted to immunoglobulin G (IgG) molecules: evidence for thyroid cell damage by IgG1, but not IgG4, autoantibodies. J. Clin. Endocrinol. Metab. 82, 925-931 (1997).
41. Weetman, A. P., Tandon, N. & Morgan. B. P. Antithyroid drugs and release of inflammatory mediators by complement-attacked thyroid cells. Lancet 340, 633-636 (1992).
42. Kagi, D. et al. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 265, 528-530 (1994).
43. Lowin, B., Hahne, M., Mattmann. C. & Tschopp, J. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas Iytic pathways. Nature 370, 650-652 (1994). References 42 and 43 were the first to show that both perforin and death-receptor pathways mediate T-cell cytotoxicity.
44. Darmon, A. J., Nicholson, D. W. & Bleackley, R. C. Activation of the apoptotic protease CPP32 by cytotoxic T-cell-derived granzyme B. Nature 377, 446-468 (1995). The first demonstration that granzyme B activates the apoptotic caspase cascade.
45. Thornberry, N. A. et al. A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis. J. Biol. Chem. 272, 17907-17911 (1997).
46. Wu, Z., Podack, E. R., McKenzie, J. M., Olsen, K. J. & Zakarija, M. Perforin expression by thyroid-infiltrating T cells in autoimmune thyroid disease. Clin. Exp. Immunol. 98, 470-477 (1994).
47. Pujol-Borrell, R., Hanafusa, T., Chiovato, L. & Bottazzo, G. F. Lectin-induced expression of DR antigen on human cultured follicular thyroid cells. Nature 304, 71-73 (1983).
48. Londei, M., Lamb, J. R., Bottazzo, G. F. & Feldmann, M. Epithelial cells expressing aberrant MHC class II determinants can present antigen to cloned human T cells. Nature 312, 639-641 (1984). References 47 and 48 were the first to show that thyrocytes can express MHC class II molecules and act as antigen-presenting cells.
49. Mackenzie, W. A. & Davies, T. F. An intrathyroidal T-cell clone specifically cytotoxic for human thyroid cells. Immunology. 61, 101-103 (1987).
50. MacKenzie, W. A., Schwartz, A. E., Friedman, E. W. & Davies, T. F. Intrathyroidal T cell clones from patients with autoimmune thyroid disease. J. Clin. Endocrinol. Metab. 64, 818-824 (1987). References 49 and 50 describe T-cell clones that are selectively cytotoxic to autologous thyroid cells.
51. + T cell lines/clones derived from autoimmune thyroiditis lesions. They recognize self-thyroid antigens directly on TEC to exhibit T helper cell 1-type lymphokine production and cytotoxicity against TEC. J. Immunol. 155, 1619-1628 (1995).
52. Hengartner, M. O. The biochemistry of apoptosis. Nature 407, 770-776 (2000).
53. Adams, J. M. & Cory, S. Life-or-death decisions by the Bcl-2 protein family. Trends Biochem. Sci. 26, 61-66 (2001).
54. Arscott, P. L. et al. Fas (APO-1, CD95)-mediated apoptosis in thyroid cells is regulated by a labile protein inhibitor. Endocrinology 138, 5019-5027 (1997).
55. Stassi, G. et al. Nitric oxide primes pancreatic β cells for Fas-mediated destruction in insulin-dependent diabetes mellitus J. Exp. Med 186, 1193-1200 (1997). Describes a new pathway that is responsible for autoimmune β-cell destruction in human diabetes.
56. Zipp, F., Krammer, P. H. & Weller, M. Immune (dys)regulation in multiple sclerosis: role of the CD95-CD95 ligand system. Immunol. Today 20, 550-554 (1999).
57. Borgerson, K. L., Bretz, J. D. & Baker. J. R. Jr. The role of Fas-mediated apoptosis in thyroid autoimmune disease Autoimmunity 30, 251-264 (1999).
58. Leithauser F. et al. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells Lab, Invest. 69, 415-429 (1993). An extensive analysis of CD95 expression in human tissues.
59. Stokes, T. A. et al. Constitutive expression of FasL in thyrocytes. Science 279. 2015A (1998).
60. Stassi, G. & De Maria, R. Response to 'Thyrocytes - not innocent bystanders in autoimmune disease'. Nature Immunol. 2, 183 (2001).
61. Hammond, L. J. et al. Analysis of apoptosis in relation to tissue destruction associated with Hashimoto's autoimmune thyroiditis. J. Pathol. 182, 138-144 (1997).
62. Mitsiades, N. et al Fas/Fas ligand up-regulation and Bcl-2 down-regulation may be significant in the pathogenesis of Hashimoto's thyroiditis. J. Clin. Endocrinol. Metab. 83, 2199-2203 (1998).
63. Batteux, F., Tourneur, L., Trebeden, H., Charreire, J. & Chiocchia, G. Gene therapy of experimental autoimmune thyroiditis by in vivo administration of plasmid DNA coding for Fas ligand. J. Immunol 162, 603-608 (1999).
64. Batteux, F., Lores, P., Bucchini, D. & Chiocchia, G. Transgenic expression of Fas ligand on thyroid follicular cells prevents autoimmune thyroiditis. J. Immunol. 164, 1681-1688 (2000).
65. Aust, G. et al. Expression of tumour necrosis factor-α (TNF-α) mRNA and protein in pathological thyroid tissue and carcinoma cell lines. Clin. Exp. Immunol. 105, 148-154 (1996).
66. Bretz, J. D., Arscott, P. L., Myc, A. & Baker, J. R. Jr. Inflammatory cytokine regulation of Fas-mediated apoptosis in thyroid follicular cells. J. Biol. Chem. 274, 25433-25438 (1999).
67. Bretz, J. D. et al. TRAIL death pathway expression and induction in thyroid follicular cells. J. Biol. Chem. 274, 23627-23632 (1999). Demonstration of a new potential pathway for thyrocyte apoptosis.
68. Bretz, J. D. & Baker, J. R. Jr. Apoptosis and autoimmune thyroid disease: following a TRAIL to thyroid destruction? Clin. Endocrinol. (Oxf) 55, 1-11 (2001).
69. Kotani, T. et al. Apoptosis in thyroid tissue from patients with Hashimoto's thyroiditis. Autoimmunity 20, 231-236 (1995).
70. Myc, A., Arscott, P. L., Bretz, J. D., Thompson, N. W. & Baker, J. R. Jr. Characterization of FAP-1 expression and function in thyroid follicular cells. Endocrinology 140, 5431-5434 (1999). A possible explanation for the refractoriness to CD95-induced apoptosis that is observed in normal thyrocytes.
71. Griffith, T. S., Brunner, T., Fletcher, S. M., Green, D. R. & Ferguson, T. A. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270, 1189-1192 (1995).
72. Stuart. R. M. et al. CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival. J. Clin. Invest. 99, 396-402 (1997).
73. Bennett, M. W. et al. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J. Immunol. 160, 5669-5675 (1998).
74. Hahne, M. et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 274, 1363-1366 (1996).
75. O'Connell, J., O'Sullivan, G. C., Collins, J. K. & Shanahan, F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med. 184, 1075-1082 (1996).
76. Allison, J., Georgiou, H. M., Strasser, A. & Vaux, D. L. Transgenic expression of CD95 ligand on islet P-cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc. Natl Acad. Sci. USA 94, 3943-3947 (1997).
77. Restifo, N. R. Not so Fas: re-evaluating the mechanisms of immune privilege and tumor escape Nature Med. 6, 493-595 (2000).
78. Kang, S. M. et al. Immune response and myoblasts that express Fas ligand. Science 278, 1322-1324 (1997).
79. Wei, Y., Chen, K., Sharp, G. C., Yagita, H. & Braley-Mullen, H. Expression and regulation of Fas and Fas ligand on thyrocytes and infiltrating cells during induction and resolution of granulomatous experimental autoimmune thyroiditis. J. Immunol. 167, 6678-6686 (2001).
80. Tourneur, L. et al. Transgenic expression of CD95 ligand on thyroid follicular cells confers immune privilege upon thyroid allografts J. Immunol. 167, 1338-1346 (2001).
81. Abbas, A. K., Murphy, K. M. & Sher, A. Functional diversity of helper T lymphocytes. Nature 383, 787-793 (1996).
82. H2 cells with related peptide specificity: relative roles of interleukin (IL)-4 and IL·10 J. Neuroimmunol. 48, 213-220 (1993).
83. H2 cells that inhibit diabetogenic lymphocytes in the nonobese diabetic mouse. J. Immunol. 183, 1696-1703 (1999).
84. Paschke, R., Schuppert, F., Taton, M. & Velu, T. Intrathyroidal cytokine gene expression profiles in autoimmune thyroiditis. J. Endocrinol. 141, 309-315 (1994).
85. Heuer, M., Aust, G., Ode-Hakim, S. & Scherbaum, W. A. Different cytokine mRNA profiles in Graves' disease, Hashimoto's thyroiditis, and nonautoimmune thyroid disorders determined by quantitative reverse transcriptase polymerase chain reaction (RT-PCR). Thyroid 6, 97-106 (1996).
86. Roura-Mir, C. et al. Single-cell analysis of intrathyroidal lymphocytes shows differential cytokine expression in Hashimoto's and Graves' disease Eur. J. Immunol. 27, 3290-3302 (1997). The first analysis of cytokine production at a single-cell level in activated T cells that infiltrate the thyroid.
87. Lombardi. G. et al. Antigen presentation by interferon-γ-treated thyroid follicular cells inhibits interleukin-2 (IL-2) and supports IL-4 production by B7-dependent human T cells. Eur. J. Immunol. 27, 62-71 (1997).
88. Racke, M. K. et al. Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J. Exp. Med. 180, 1961-1966 (1994).
89. Buer, J. et al. Interleukin 10 secretion and impaired effector function of major histocompatibility complex class II-restricted T cells anergized in vivo. J. Exp. Med. 187, 177-183 (1998).
90. Fiorentino, D. F., Zlotnik, A., Mosmann, T. R., Howard, M. & O'Garra, A. IL-10 inhibits cytokine production by activated macrophages. J. Immunol. 147, 3815-3822 (1991).
91. Cunha, F. Q., Moncada, S. & Liew, F. Y. Interleukin-10 (IL-10) inhibits the induction of nitric oxide synthase by interferon-γ in murine macrophages Biochem. Biophys. Res. Commun. 182, 1155-1159 (1992).
92. Batteux, F., Trebeden, H., Charreire, J. & Chiocchia, G. Curative treatment of experimental autoimmune thyroiditis by in vivo administration of plasmid DNA coding for interleukin-10. Eur. J. Immunol. 29. 958-963 (1999).
93. Asseman, C., Mauze, S., Leach, M. W., Coffman, R. L. & Powrie, F. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J. Exp. Med. 190, 995-1004 (1999).
94. Kawakami, A. et al. Thyroid-stimulating hormone inhibits Fas antigen-mediated apoptosis of human thyrocytes in vitro. Endocrinology 137, 3163-3169 (1996).
95. Koga, M. et al. Immunohistochemical analysis of Bcl-2, Bax, and Bak expression in thyroid glands from patients with subacute thyroiditis. J. Clin. Endocrinol. Metab. 84, 2221-2225 (1999).